MLICM
CCCC icon

Metropolitan Life Insurance Company (MetLife)’s C4 Therapeutics CCCC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,107
Closed -$3.48K – 2468
2023
Q1 		$3.48K Sell
1,107
-1,476
-57% -$8.69K ﹤0.01% 2286
2022
Q4 		$15.2K Hold
2,583
– – ﹤0.01% 2127
2022
Q3 		$22.7K Hold
2,583
– – ﹤0.01% 1969
2022
Q2 		$19.5K Hold
2,583
– – ﹤0.01% 2067
2022
Q1 		$62.7K Sell
2,583
-7,792
-75% -$189K ﹤0.01% 1465
2021
Q4 		$334K Hold
10,375
– – ﹤0.01% 1680
2021
Q3 		$464K Sell
10,375
-10,021
-49% -$429K 0.01% 1515
2021
Q2 		$772K Buy
20,396
+16,659
+446% +$597K 0.01% 1672
2021
Q1 		$138K Hold
3,737
– – ﹤0.01% 2260
2020
Q4 		$124K Buy
+3,737
New +$108K ﹤0.01% 2245

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CCCC Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 1,107 shares — an estimated $3.48K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CCCC in Q4 2020 and held it in 10 quarters. The position peaked at $772K in Q2 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,107 C4 Therapeutics shares in Q2 2023, an estimated $3.48K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in C4 Therapeutics in Q4 2020 and held it in 10 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s C4 Therapeutics position peaked at $772K in Q2 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.